Novo Nordisk blueprints $1.2B rare disease production ... While Novo has at long last won regulatory recognition for concizumab in the U.S., the path to approval has been anything but easy.

The US Food and Drug Administration approved 50 new molecular entities in 2024 —just five fewer than it did in 2023. Last ...

Novo Nordisk's anti-TFPI antibody concizumab has been backed for approval in the EU as a once-daily drug to prevent bleeding episodes in people with haemophilia. The recommendation by the EMA's ...

Denmark-based pharma giant Novo Nordisk has announced plans to invest ... The company’s haemophilia portfolio includes Alhemo (concizumab) and its antibody asset Mim8, with the Phase III ...

With Alhemo (concizumab-mtci) from Novo Nordisk A/S, a third hemophilia drug in the past eight months has been approved by the U.S. FDA. The once-daily injectable prophylaxis is to prevent or reduce ...

recommending the approval of Alhemo (concizumab) for haemophilia A or B with inhibitors. A final decision is expected soon. Alhemo is not approved in the United States. Novo Nordisk is trading ...

The U.S. FDA has approved Alhemo, given as once-daily injections, to help prevent bleeds in patients with hemophilia A or B ...

Novo Nordisk has secured approval from the US Food and Drug Administration (FDA) for Alhemo (concizumab-mtci) as a once-daily treatment to prevent or reduce bleeding episodes in adults and ...